Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.36 |
| ▸ | TTR | P02766 | 2/20 | 0.35 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.34 |
| ▸ | CTSD | P07339 | 2/20 | 0.34 |
| ▸ | CTSE | P14091 | 2/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15031315 | 0.96 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRNTSR1 | |
| SCHEMBL13838247 | 0.94 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRCTSD | |
| SCHEMBL2734901 | 0.94 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRCTSD | |
| SCHEMBL10285897 | 0.94 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRCTSD | |
| SCHEMBL19144617 | 0.94 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRCTSD | |
| SCHEMBL23967978 | 0.94 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRCTSD | |
| SCHEMBL20075905 | 0.94 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRCTSD | |
| SCHEMBL21087578 | 0.92 | SSTR2 (0.42) | CYP3A4SSTR2FOLH1TTRNTSR1 | |
| SCHEMBL14850595 | 0.92 | SSTR2 (0.42) | CYP3A4SSTR2FOLH1TTRNTSR1 | |
| SCHEMBL19490727 | 0.91 | CYP3A4 (0.42) | CYP3A4SSTR2FOLH1TTRCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210095043-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20180133315-A1 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE | HOFFMANN-LA ROCHE INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210095043-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | LGALS3BP, PABPC4, PA2G4 | CYP3A4 3333/4885SSTR2 4444/4885FOLH1 264/4885 |
| US-20180133315-A1 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE | CD99, CD209, SIGLEC9 | CYP3A4 1226/4885SSTR2 2355/4885FOLH1 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.